Novartis and Microsoft have agreed to a five-year partnership to use artificial intelligence (AI) to develop new drugs faster, and with greater precision.
Novartis CEO Vas Narasimhan said AI's potential for personalized medicine is particularly promising, as it will help classify subgroups of patients that new drugs will most likely benefit, using clinical and preclinical datasets.
Narasimhan added that these datasets were consolidated from Novartis' internal information, surmounting integration obstacles.
The ultimate goal of the alliance is to use AI to fuel research, development, manufacturing, finance, sales, marketing, and acquisitions.
The partners initially will target their application of AI to personalized treatments for macular degeneration, cell and gene therapy, and drug design.
From Financial Times
View Full Article - May Require Paid Subscription
Abstracts Copyright © 2019 SmithBucklin, Washington, DC, USA
No entries found